Invesco Preferred ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Invesco Preferred ETF trades at $10.46, while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Invesco Preferred ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| PGX | REGN | |
|---|---|---|
52-Week High | $11.87 | $852.03 |
52-Week Low | $10.46 | $555.51 |
Market Cap | — | $83.43B |
Sector | — | Health |
Enterprise Value | — | $78.14B |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.49 with no change in the last 24 hours. Technical indicators show a bearish trend from moving averages but bullish signals from oscillators, with support at $10 and resistance at $11. Recent corporate actions include dividends declared for H1-26 and H2-26, though key financial ratios are unavailable for fundamental assessment.
The outlook remains uncertain due to limited financial data. Opportunities include dividend income, but risks stem from the lack of transparency in earnings and valuation metrics. Investors should seek updated SEC filings for a clearer picture of the company's health and growth prospects.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →